Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families

(2009) DGR Evans et al.   CLINICAL GENETICS

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

The Contribution of BRCA1 and BRCA2 to Ovarian Cancer

(2009) Susan J. Ramus et al.   Molecular Oncology

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE